ATAZANAVIR CAPSULES
(ATAZANAVIRI CAPSULAE)

Draft revision for The International Pharmacopoeia
(March 2018)

DRAFT FOR COMMENT

Should you have any comments on this draft, please send these to Dr Herbert Schmidt, Medicines Quality Assurance Programme, Technologies Standards and Norms, Department of Essential Medicines and Health Products, World Health Organization, 1211 Geneva 27, Switzerland; fax: (+41 22) 791 4730 or email: schmidt@who.int by 11 May 2018.

In order to speed up the process for receiving draft monographs and for sending comments, please let us have your email address (to bonnyw@who.int) and we will add it to our electronic mailing list. Please specify if you wish to receive monographs.

© World Health Organization 2018

All rights reserved.

This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations’ concerned staff and member organizations) without the permission of the World Health Organization. The draft should not be displayed on any website.

Please send any request for permission to:

Dr Sabine Kopp, Manager, Medicines Quality Assurance Programme, Technologies Standards and Norms, Department of Essential Medicines and Health Products, World Health Organization, CH-1211 Geneva 27, Switzerland.

Fax: (41-22) 791 4730; email: kopp@who.int.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft. However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.
SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/17.739:
Draft revision for *The International Pharmacopoeia*

ATAZANAVIR CAPSULES
(*ATAZANAVIRI CAPSULAE*)

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>First draft received from collaborating laboratory</td>
<td>September 2017</td>
</tr>
<tr>
<td>Submission to the fifty-second meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations</td>
<td>16–20 October 2017</td>
</tr>
<tr>
<td>Draft revision sent out for public consultation</td>
<td>March–May 2018</td>
</tr>
<tr>
<td>Further follow-up action as required</td>
<td></td>
</tr>
</tbody>
</table>

[Note from the Secretariat: Following laboratory investigations performed to establish Atazanavir sulfate ICRS it is proposed to revise the monograph on Atazanavir capsules with a view to:

- update the information given under Additional information to reflect the information given in the 20th WHO Model List of Essential Medicines;
- use the absorptivity value of atazanavir sulfate to calculate the result of the dissolution test and assay method B.

Changes from the current monograph are indicated in the text by insert or delete.]
ATAZANAVIR CAPSULES  
(ATAZANAVIRI CAPSULAE)

Category. Antiretroviral (protease inhibitor).

Storage. Atazanavir capsules should be kept in a tightly closed container.

Additional information. Strength in the current WHO Model List of Essential Medicines (EML): 100 mg, 150 mg, 300 mg of atazanavir (as sulfate). Strength in the current WHO EML for Children: 100 mg, 150 mg, 300 mg of atazanavir (as sulfate).

Each mg of atazanavir (C38H52N6O7) is equivalent to 1.139 mg of atazanavir sulfate (C38H52N6O7•H2SO4).

Requirements

Comply with the monograph for Capsules.

Definition

Atazanavir capsules contain atazanavir sulfate. They contain not less than 90.0% and not more than 110.0% of the amount of atazanavir, C38H52N6O7, stated on the label.

Each mg of atazanavir (C38H52N6O7) is equivalent to 1.139 mg of atazanavir sulfate (C38H52N6O7•H2SO4).

Identity tests

A. Carry out test A.1, or where UV detection is not available, test A.2.

A.1 Carry out the test as described under 1.14.1 Thin-layer chromatography using silica gel R6 as the coating substance and a mixture of 9.5 volumes of dichloromethane R and 0.5 volume of 2-propanol R as the mobile phase. Apply separately to the plate 10 µL of each of the following 2 solutions in methanol R. For solution (A) disperse a quantity of the contents of the capsules containing about 20 mg of atazanavir in 10 mL of methanol R, sonicate for 10 minutes, allow to cool to room temperature, dilute to 20 mL, filter and use the filtrate. For solution (B) use 1.1 mg of atazanavir sulfate RS per mL.

After removing the plate from the chromatographic chamber allow it to dry exhaustively in air or a current of air. Examine the chromatogram in ultraviolet light (254 nm).

The principal spot obtained with solution (A) corresponds in position, appearance and intensity to that obtained with solution (B).

A.2 Carry out the test as described under 1.14.1 Thin-layer chromatography using the conditions described above under test A.1 but using a plate containing silica gel R5
as the coating substance. Spray with basic potassium permanganate (~5 g/L) TS. Examine the chromatogram in daylight.

The principal spot obtained with solution (A) corresponds in position, appearance and intensity with that obtained with solution (B).

B. Disperse a quantity of the contents of the capsules containing about 20 mg of atazanavir in 10 mL of methanol R, sonicate for 10 minutes, allow to cool to room temperature, dilute to 20 mL and filter. Dilute 1.0 mL of the filtrate to 100.0 mL with methanol R. The absorption spectrum (1.6) of the resulting solution, when observed between 230 and 340 nm, exhibits two maxima at about 250 nm and 280 nm.

C. To a quantity of the contents of the capsules equivalent to 0.2 g of atazanavir add 10 mL of a mixture of 1 volume of water R and 1 volume of acetonitrile R, shake and filter. The filtrate yields Reaction A described under 2.1 General identification tests as characteristic of sulfates.

**Dissolution**

Carry out the test as described under 5.5 Dissolution test for solid oral dosage forms using as the dissolution medium 900 mL of dissolution buffer pH 2.5 TS and rotating the paddle at 50 revolutions per minute. At 45 minutes withdraw a sample of 10.0 mL of the medium through an in-line filter. Allow the filtered sample to cool to room temperature.

Dilute a suitable volume of the filtrate with dissolution medium to obtain a solution containing 0.10 mg of atazanavir per mL. Measure the absorbance (1.6) of a 1 cm layer of the resulting solution, suitably diluted with the dissolution buffer if necessary, at the maximum at about 250 nm, using the dissolution medium as the blank. Measure at the same time and under the same conditions the absorbance of a suitable solution of atazanavir sulfate RS in the dissolution medium.

For each of the capsules tested, calculate the total amount of atazanavir (C_{38}H_{52}N_{6}O_{7}) in the medium, using an absorptivity value of 11.4 for atazanavir sulfate (A_{1cm} = 114) using the declared content of C_{38}H_{52}N_{6}O_{7} in atazanavir sulfate RS. Each mg of atazanavir sulfate (C_{38}H_{52}N_{6}O_{7}•H_{2}SO_{4}) is equivalent to 1.139 mg of atazanavir (C_{38}H_{52}N_{6}O_{7}). Evaluate the results as described under 5.5 Dissolution test for solid dosage forms. **Acceptance criteria.** The amount in solution for each capsule is not less than 75% (Q) of the amount stated on the label.

**Note from the Secretariat.** It is intended to determine the absorptivity value of atazanavir during the establishment of atazanavir sulfate RS and to use this value for the calculation of the test result.
**Related substances**

Carry out the test as described under 1.14.4 *High-performance liquid chromatography* using a stainless steel column (150 mm x 4.6 mm) packed with end-capped base-deactivated particles of silica gel, the surface of which has been modified with chemically-bonded octylsilyl groups (5 μm). Use the following conditions for gradient elution:

- **Mobile phase A:** 0.02 M phosphate buffer pH 3.5, acetonitrile R (70:30 v/v);
- **Mobile phase B:** 0.02 M phosphate buffer pH 3.5, acetonitrile R (30:70 v/v).

Prepare the 0.02 M phosphate buffer pH 3.5 by dissolving 2.72 g of anhydrous potassium dihydrogen phosphate R in 800 mL of water R, adjust the pH to 3.5 by adding phosphoric acid (~105 g/L) and dilute to 1000 mL with water R.

<table>
<thead>
<tr>
<th>Time (minutes)</th>
<th>Mobile phase A (% v/v)</th>
<th>Mobile phase B (% v/v)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–2</td>
<td>100</td>
<td>0</td>
<td>Isocratic</td>
</tr>
<tr>
<td>2–10</td>
<td>100 to 75</td>
<td>0 to 25</td>
<td>Linear gradient</td>
</tr>
<tr>
<td>10–30</td>
<td>75 to 50</td>
<td>25 to 50</td>
<td>Linear gradient</td>
</tr>
<tr>
<td>30–45</td>
<td>50 to 50</td>
<td>50 to 100</td>
<td>Linear gradient</td>
</tr>
<tr>
<td>45–50</td>
<td>0</td>
<td>100</td>
<td>Isocratic</td>
</tr>
<tr>
<td>50–52</td>
<td>0 to 100</td>
<td>100 to 0</td>
<td>Linear gradient</td>
</tr>
<tr>
<td>52–60</td>
<td>100</td>
<td>0</td>
<td>Isocratic</td>
</tr>
</tbody>
</table>

Prepare the following solutions using as diluent a mixture of equal volumes of acetonitrile R and water R. For solution (1) weigh and mix the contents of 20 capsules. Transfer a quantity of the mixed contents equivalent to 20 mg of atazanavir into a 20 mL volumetric flask. Add about 10 mL of the diluent, sonicate for 10 minutes, allow to cool to room temperature, make up to volume and filter. For solution (2) dilute 1.0 mL of solution (1) to 100.0 mL with a suitable volume of solution (1) with the diluent to obtain a concentration of 10 μg of atazanavir per mL. For solution (3) mix 1 mL of solution (1) with 4.5 mL of water R and 0.5 mL of sodium hydroxide (10 g/L) TS and heat the mixture in a water bath at 85 °C for 15 minutes.

Operate with a flow rate of 1.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 250 nm. Maintain the column at a temperature of 30 °C.
Inject 20 µL of solution (3). The test is not valid unless the resolution between the peak due to atazanavir (retention time about 22 minutes) and the peak with a relative retention of about 1.2 is at least 4.

Inject alternatively 20 µL each of solutions (1) and (2).

In the chromatograms obtained with test solution (1):

- the area of any peak, other than the principal peak, is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (1.0%);

- the sum of the areas of all peaks, other than the principal peak, is not greater than twice the area of the principal peak in the chromatogram obtained with solution (2) (2.0%). Disregard any peak with an area less than 0.1 times the area of the principal peak in the chromatogram obtained with solution (2) (0.1%).

**Assay**

- Either test A or test B may be applied.

**A.** Carry out the test as described under 1.14.4 High-performance liquid chromatography using a stainless steel column (150 mm x 4.6 mm) packed with end-capped base-deactivated particles of silica gel, the surface of which has been modified with chemically-bonded octylsilyl groups (5 μm).

As the mobile phase use a solution prepared as follows: 60 volumes of acetonitrile R and 40 volumes of 0.02 M phosphate buffer pH 3.5. Prepare the 0.02 M phosphate buffer pH 3.5 according to the procedure described in the related substances test.

Prepare the following solutions using as diluent a mixture of equal volumes of acetonitrile R and water R. For solution (1) weigh and mix the contents of 20 capsules. Transfer a quantity equivalent to 20.0 mg of atazanavir, accurately weighed, into a 20 mL volumetric flask. Add about 10 mL of the diluent, sonicate for about 10 minutes, allow to cool to room temperature and make up to volume. Filter a portion of this solution, discarding the first few mL. Dilute 5.0 mL of the filtrate to 50.0 mL with the diluent. For solution (2) use 0.11 mg of atazanavir sulfate RS per mL.

Operate with a flow rate of 1.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 250 nm. Maintain the column at a temperature of 30 °C.

Inject alternately 20 µL each of solutions (1) and (2) and record the chromatograms for 1.5 times the retention time of atazanavir (about 4 minutes).
Measure the areas of the peak responses obtained in the chromatograms from solutions (1) and (2) and calculate the percentage content of atazanavir, (C\textsubscript{38}H\textsubscript{52}N\textsubscript{6}O\textsubscript{7}) in the capsules, using the declared content of C\textsubscript{38}H\textsubscript{52}N\textsubscript{6}O\textsubscript{7} in atazanavir sulfate RS.

B. Weigh and mix the contents of 20 capsules. Transfer a quantity equivalent to 20 mg of atazanavir, accurately weighed, to a 20 mL volumetric flask. Add about 10 mL of methanol R, sonicate for about 10 minutes, allow to cool to room temperature and make up to volume with methanol R. Filter a portion of this solution, discarding the first few mL of the filtrate. Dilute 1.0 mL of the filtrate to 10.0 mL with methanol R. Measure the absorbance (I.6) of a 1 cm layer of this solution in at the maximum at about 250 nm, using methanol R as a blank. Measure at the same time and under the same conditions the absorbance of a suitable solution of atazanavir sulfate RS in methanol R. Calculate the percentage content of C\textsubscript{38}H\textsubscript{52}N\textsubscript{6}O\textsubscript{7} in the capsules using an absorptivity value of 14.5 for atazanavir sulfate (A\textsubscript{1 cm}^\% = 145), using the declared content of C\textsubscript{38}H\textsubscript{52}N\textsubscript{6}O\textsubscript{7} in atazanavir sulfate RS. Each mg of atazanavir sulfate (C\textsubscript{38}H\textsubscript{52}N\textsubscript{6}O\textsubscript{7}•H\textsubscript{2}SO\textsubscript{4}) is equivalent to 1.139 mg of atazanavir (C\textsubscript{38}H\textsubscript{52}N\textsubscript{6}O\textsubscript{7}).

\textit{Note from the Secretariat. It is intended to determine the absorptivity value of atazanavir during the establishment of atazanavir sulfate RS and to use this value for the calculation of the test result.}